We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

OPAP:ATHEXGreek Organisation of Football Prognostics SA Analysis

Data as of 2026-03-14 - not real-time

€14.80

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

OPAP is trading well below its short‑term and intermediate moving averages, signalling a bearish technical backdrop. The momentum indicator sits in the lower‑mid range, while the MACD has just turned bullish, hinting at a possible short‑term rebound. Volume has been slipping, suggesting waning buying interest despite a solid cash‑flow profile. The dividend yield remains exceptionally high, but the payout ratio is near the top of earnings, raising questions about sustainability. A discounted cash‑flow model points to a substantial upside potential, implying the market may be undervaluing the stock. However, the balance sheet is heavily leveraged, and the gambling sector faces moderate regulatory scrutiny in Greece and Cyprus.
From a valuation standpoint the stock appears undervalued relative to intrinsic estimates, yet the high dividend payout and leverage temper enthusiasm. The low systematic risk reflected by a modest beta contrasts with elevated recent price volatility and a decreasing liquidity trend. Over the medium to long horizon, the company’s dominant market position and strong cash generation could support a recovery, provided regulatory conditions remain stable.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price below key moving averages
  • decreasing trading volume
  • high dividend payout straining earnings

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF‑derived upside potential
  • low beta indicating limited market‑wide volatility
  • strong operating cash flow supporting dividend

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • dominant market position in Greek and Cypriot gambling
  • sustained cash generation despite leverage
  • potential for regulatory stability enhancing predictability

Key Metrics & Analysis

Financial Health

Revenue Growth0.60%
Profit Margin29.41%
P/E Ratio11.0
ROE94.76%
ROA20.45%
Debt/Equity226.72
P/B Ratio12.5
Op. Cash Flow€716.5M
Free Cash Flow€566.7M

Technical Analysis

TrendBearish
RSI36.2
Support€14.10
Resistance€17.19
MA 20€15.43
MA 50€16.90
MA 200€18.45
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value€21.49
Target Price€19.57
Upside/Downside32.24%
GradeUndervalued
TypeValue
Dividend Yield12.86%

Risk Assessment

Beta0.36
Volatility36.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.